Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

BACKGROUND: Antagonizing the androgen-receptor (AR) pathway is an effective treatment strategy for patients with metastatic castration-resistant prostate cancer (CRPC). Here, we report the results of a first-in-human phase 1/2 study which assessed the safety, pharmacokinetics, and activity of SHR368...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xiaojian, Ji, Dongmei, Gu, Weijie, Han, Weiqing, Luo, Hong, Du, Chuanjun, Zou, Qing, Sun, Zhongquan, He, Chaohong, Zhu, Shaoxing, Chong, Tie, Yao, Xin, Wan, Ben, Yang, Xinfeng, Bai, Aobing, Jin, Chunlei, Zou, Jianjun, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895828/
https://www.ncbi.nlm.nih.gov/pubmed/35241087
http://dx.doi.org/10.1186/s12916-022-02263-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895828/
https://www.ncbi.nlm.nih.gov/pubmed/35241087
http://dx.doi.org/10.1186/s12916-022-02263-x

Ejemplares similares